Metrics as of 10/13/2026, 06:50 PM (Berlin time), refresh in progress.
Talphera Stock
Talphera, Inc.
Company data
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- CEO
- Vincent J. Angotti
- Employees
- 12
- Market cap
- $56 M
- IPO
- 11/02/2011
- Web
- talphera.com
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being…
Talphera stock: price history
1D
+0.9%
1W
+0.0%
1M
-9.2%
6M
+34.6%
YTD
-5.3%
1Y
-6.9%
2Y
+29.7%
5Y
-94.7%
10Y
-98.4%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~29% stronger price swings than usual
Ask the agents about Talphera
Analyst assessment of Talphera
PRICE TARGET LOW
US$3.00
CONSENSUS
US$3.00
MEDIAN
US$3.00
PRICE TARGET HIGH
US$3.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 01/04/2025
Talphera stock metrics
P/E
-3.38
P/B
5.66
EV/EBITDA
-3.86
RETURN ON EQUITY
-29.9%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
51.7%
FLOAT SHARES
26,831,080
AVG. DAILY VOLUME (30D)
134,994
Insider transactions (SEC)
HOFFMAN STEPHEN J
WAN MARK A
ADAMS ADRIAN
Broadfoot Jill Marie
Todisco Joseph
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Talphera stock
What does Talphera do?
Talphera, Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Vincent J. Angotti, the company employs around 12 people.
The IPO was on 11/02/2011; the stock trades on NASDAQ under the ticker TLPH.
What do analysts say about Talphera stock?
1 analysts rate the stock, the consensus is Buy (as of 01/04/2025).
The average price target is US$3.00, ranging from US$3.00 to US$3.00, with a median of US$3.00.
This is an external assessment, not a statement by Market Jury.
When does Talphera report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 29% stronger than usual.
Does Talphera pay a dividend?
No, Talphera currently does not pay a dividend.
Which stocks are comparable to Talphera?
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences and Amphastar Pharmaceuticals.
How can I get Talphera stock analyzed?
Clicking "Analyze stock" lets five strategies assess Talphera against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.